RVL Pharmaceuticals plc (RVLP) Research

RVL Pharmaceuticals plc operates as a specialized pharmaceutical firm, concentrating on the creation and commercialization of medicinal products. These offerings target patient populations with unmet needs within the fields of ocular health and medical aesthetics across the United States, Argentina, and Hungary. Among its key commercialized products is Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution specifically developed for adults experiencing acquired blepharoptosis, or drooping eyelids. The company, whose corporate headquarters are located in Bridgewater, New Jersey, underwent a name change in January 2022, transitioning from its former identity as Osmotica Pharmaceuticals plc.

Market snapshot

Symbol
RVLP
Price
$0.03
Day change
-32.05%
Market cap
$3.1M
P/E ratio
-0.05x
52-week range
0.0026-1.66
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Affimed N.V. (AFMD)
  • Aravive, Inc. (ARAV)
  • Atreca, Inc. (BCEL)
  • Biophytis S.A. (BPTS)
  • Eiger BioPharmaceuticals, Inc. (EIGRQ)
  • Gritstone bio, Inc. (GRTS)
  • Idera Pharmaceuticals, Inc. (IDRA)
  • Onconetix, Inc. (ONCO)

Recent insider activity

  • Harsaul Foundation — S-Sale (9363760 shares) on 2023-10-19
  • Harsaul Foundation — S-Sale (4758899 shares) on 2023-10-20
  • Altchem Ltd — S-Sale (9363760 shares) on 2023-10-19
  • Altchem Ltd — S-Sale (4758899 shares) on 2023-10-20
  • Harsaul Foundation — S-Sale (3421537 shares) on 2023-10-18

Open RVL Pharmaceuticals plc (RVLP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.